Enanta Pharmaceuticals (ENTA) Non-Current Assets (2012 - 2026)

Enanta Pharmaceuticals' Non-Current Assets history runs 15 years deep, the most recent figure standing at $136.3 million for Q1 2026.

• Quarterly Non-Current Assets rose 70.08% year-over-year to $136.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $421.8 million (up 20.64% YoY) and the FY2025 annual result came in at $76.4 million, down 0.53% from the prior year.
• Non-Current Assets was $136.3 million for Q1 2026 at Enanta Pharmaceuticals, up from $130.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $136.3 million in Q1 2026 and bottomed at $38.2 million in Q4 2023.
• A 5-year average of $75.2 million and a median of $72.2 million in 2022 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets plunged 46.82% — and 2024, when it surged 140.32%.
• Enanta Pharmaceuticals' Non-Current Assets stood at $63.8 million in 2022, then tumbled by 40.16% to $38.2 million in 2023, then surged by 110.75% to $80.5 million in 2024, then jumped by 62.51% to $130.8 million in 2025, then rose by 4.18% to $136.3 million in 2026.
• Business Quant data shows ENTA's Non-Current Assets at $136.3 million in Q1 2026, $130.8 million in Q4 2025, and $76.4 million in Q3 2025.